PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Circulation. Author manuscript; available in PMC 2010 October 27.
Published in final edited form as:
PMCID: PMC2783481
NIHMSID: NIHMS153743

NOS1AP is a Genetic Modifier of the Long-QT Syndrome

Lia Crotti, M.D., Ph.D.,1,2,3 Maria Cristina Monti, Ph.D.,4,5 Roberto Insolia, B.Sc.,3 Anna Peljto, M.S.,5 Althea Goosen, B.Sc.,6 Paul A. Brink, M.D.,7 David A. Greenberg, Ph.D.,5 Peter J. Schwartz, M.D.,1,2,3,7,8,9,* and Alfred L. George, Jr., M.D.10,11,12,*

Abstract

Background

In congenital long-QT syndrome (LQTS), a genetically heterogeneous disorder that predisposes to sudden cardiac death, genetic factors other than the primary mutation may modify the probability of life-threatening events. Recent evidence indicates that common variants in NOS1AP are associated with the QT interval duration in the general population.

Methods and Results

We tested the hypothesis that common variants in NOS1AP modify the risk of clinical manifestations and the degree of QT interval prolongation in a South African LQTS population (500 subjects, 205 mutation carriers) segregating a founder mutation in KCNQ1 (A341V) using a family-based association analysis. NOS1AP variants were significantly associated with the occurrence of symptoms (rs4657139, p=0.019; rs16847548, p=0.003), with clinical severity as manifested by a greater probability for cardiac arrest and sudden death (rs4657139, p=0.028; rs16847548, p=0.014), and with greater likelihood of having a QT interval in the top 40% of values among all mutation carriers (rs4657139, p=0.03; rs16847548, p=0.03).

Conclusions

These findings indicate that NOS1AP, a gene first identified as affecting the QTc interval in a general population, also influences sudden death risk in subjects with LQTS. The association of NOS1AP genetic variants with risk for life-threatening arrhythmias suggests that this gene is a genetic modifier of LQTS and this knowledge may be clinically useful for risk-stratification for patients with this disease, after validation in other LQTS populations.

Keywords: long-QT syndrome, nitric oxide synthase, KCNQ1, genetics, arrhythmia

Introduction

The congenital long-QT syndrome (LQTS) is an inherited disorder of abnormal myocardial repolarization in which there is a high risk for potentially lethal cardiac arrhythmias.1 The disorder is caused by mutations in several genes most of which encode ion channel subunits involved in the regulation of the cardiac action potential. The most common form of LQTS (LQT1) is caused by mutations in KCNQ1, a gene encoding the pore-forming subunit of potassium channels responsible for the slow cardiac delayed rectifier current.2 In many families, LQTS exhibits incomplete penetrance and variable expressivity, which suggest the existence of factors other than the primary mutation that can modify the probability of symptoms.3-6 Identification of genetic modifiers of LQTS would lead to improved risk stratification among mutation carriers and could also provide information about the risk for life-threatening arrhythmias in more common conditions, such as acute myocardial infarction and congestive heart failure.

A prolonged QT interval is a surrogate measurement of prolonged ventricular repolarization and is a widely recognized subclinical marker for increased risk of life-threatening cardiac arrhythmia in congenital and acquired forms of LQTS and after a myocardial infarction.7,8 A recent genome wide association study identified genetic variation in NOS1AP, which encodes a nitric oxide synthase adaptor protein, as a contributor to QT interval duration in the general population9. Although the absolute quantitative effect of NOS1AP variants on the QT interval in healthy subjects was small, explaining up to 1.5% of QT interval variation, the replication of this finding in several distinct populations demonstrated that the association is robust.10-18 Further analyses have found an association between NOS1AP and risk for sudden death in a general population19 and increased cardiovascular mortality in users of calcium channel blockers.20 Whether genetic variation in NOS1AP contributes to the risk of sudden death in congenital LQTS is not known.

We tested the hypothesis that NOS1AP is a genetic modifier of LQTS in a South African population segregating the KCNQ1-A341V mutation and exhibiting variable disease expression among mutation carriers.21 This population is particularly well suited for testing genetic modifier hypotheses because all at-risk subjects share the same disease-causing mutation, a feature that offers advantages over using LQTS populations having heterogeneous mutations in multiple different genes, a factor known to confer varying levels of arrhythmia risk.22-24

Methods

Study Population

We studied a LQT1 South African founder population of mixed Dutch and French Huguenot origin harboring a mutation in KCNQ1 (A341V).21 Cardiac events were defined as syncope (fainting spells with transient, but complete, loss of consciousness), aborted cardiac arrest (requiring resuscitation) and sudden cardiac death. Mutation carriers were classified as either symptomatic or asymptomatic. Symptomatic subjects were mutation carriers who experienced at least one cardiac event, whereas to be defined asymptomatic, a mutation carrier had to be at least 15 years old and not treated with β-adrenergic receptor antagonists. Additionally, symptomatic mutation carriers were classified by the severity of their clinical manifestations into two groups: those with a severe form of the disease (cardiac arrest and/or sudden cardiac death) and those with a milder form of the disease (symptomatic patients with no cardiac arrest/sudden cardiac death). Baseline electrocardiograms (ECGs) recorded in the absence of β-blocker therapy were coded and subsequently analyzed by one investigator (L.C.) blinded to genotype. Baseline heart rate (HR) and duration of the QT and RR intervals in leads II and V3 were measured from resting 12-lead ECGs. To allow QT values to be compared among subjects, the QT interval was corrected for heart rate (QTc) by using Bazett's formula.

All probands and family members provided written informed consent for clinical and genetic testing. Protocols were approved by the Ethical Review Boards of the Tygerberg Hospital of Stellenbosch University and the University of Pavia, and the Vanderbilt University Institutional Review Board. Approved consent forms were provided in English or Afrikaans as appropriate.

Genotyping

Genotyping of index cases and family members for the A341V mutation was previously described.21 The NOS1AP variants rs4657139, rs16847548, rs12567209, rs10494366, rs6683968 were genotyped using the 5′ nucleotidase TaqMan assay (ABI Prism 7900HT, Applied Biosystems, Foster City, CA). Three of these variants (rs10494366, rs4657139, rs6683868)9,11,25 were among the first to be tested for association with QT interval in general populations while the remaining two variants (rs16847548, rs12567209) were associated with sudden cardiac death in a community-based study.19 Figure 1A provides the minor allele frequency (MAF) for each of the tested polymorphisms in our population and in the western European ancestry sample of the HapMap Project.

Fig. 1
Variants and linkage disequilibrium (LD) in NOS1AP. (A) Minor allele frequencies for each NOS1AP variant observed in the study population and in the western European ancestry sample of the HapMap Project (numbers in parentheses). The minor allele listed ...

Statistical Analysis

Data are reported as mean and standard deviation (SD) for continuous variables; whenever the distribution was skewed, median, interquartile range (IQR) or quintiles were reported. Differences in baseline characteristics among groups of subjects were assessed with either a t-test or χ2 test. Two-sided p-values <0.05 were considered statistically significant.

Association analyses were performed using the pedigree disequilibrium test (PDT) that allows the use of related trios and discordant sibpairs from extended pedigrees to identify associations of disease and marker.26 Extended pedigrees are ideal suited for analysis by PDT and the program is robust to any non-independence among pedigrees.27 In the original description of this founder population, there were 22 extended pedigrees including up to 5 generations that could be genealogically linked.21 Because PDT can only handle up to 3-generation families, we sub-divided the founder population into a series of 49 non-overlapping 3-generation pedigrees. Triads were then defined as informative nuclear families in which there is at least one affected child, both parents genotyped at the marker and at least one heterozygous parent. Discordant sibpairs were also informative if they had at least one affected and one unaffected sibling with different marker genotypes, with or without parental genotype data. Informative extended pedigrees contained at least one informative nuclear family and/or discordant sibship. Affectedness status of subjects was depended on the phenotype of interest: symptomatic mutation carriers, symptomatic mutation carriers with a severe form of the disease or mutation carriers with a prolonged QTc.

Because we examined association with up to 5 variants, we applied a correction for multiple testing based on the spectral decomposition (SpD) of matrices of the pairwise correlation coefficient (r) between variants.28,29 This method estimates the effective number of independent markers (Meff-Li) by taking account of the intermarker LD; the test criteria is then adjusted by the Bonferroni correction as though there were Meff-Li independent tests. Using this approach, we determined that there were 4 effectively independent tests among the 5 genotyped NOS1AP variants. Therefore, in the initial PDT association analysis between symptoms and NOS1AP genotype, we used a corrected α-level of 0.0125 (0.05/4) as the threshold for statistical significance.

We also carried out an empirical calculation of the type I error level, which is not dependent on any explicit or hidden statistical assumptions of the PDT method. Using the extensive computer simulation facility developed by one of the authors (Pedpower, D.A.G.), a computer simulation randomly assigned marker genotypes to the exact family structures of the families in the data set. Marker and disease loci were simulated to be biallelic, and the loci were in linkage equilibrium. The relationship of the markers to the disease locus represented the null hypothesis, that is, there was no association between the disease and the marker. We simulated 10,000 such data sets and showed that the false positive rate followed a χ2 distribution. Thus, the particular characteristics of this data set represented no unusual or confounding problems to the PDT.

Statistical calculations were performed by using STATA 10 (StataCorp, College Station, Texas 77845 USA) and the PDT software (http://www.chg.duke.edu/research/pdt.html). Linkage disequilibrium (LD) across NOS1AP was evaluated using Haploview (http://www.broad.mit.edu/mpg/haploview) using the HapMap data for this region (http://www.hapmap.org). The r2 correlation coefficient (Figure 1B) and the normalized disequilibrium coefficient (D′) were used as a measure of LD.30

Statement of Responsibility

The authors had full access to the data and take responsibility for its integrity. All authors have read and agree to the manuscript as written.

Results

Study Population

We studied a South African LQT1 (KCNQ1-A341V mutation) population that consisted of 500 family members of whom 205 were mutation carriers, 228 were non-carriers, and 67 were not genetically tested. For this study, DNA samples were available on 255 subjects. There was no sex bias (females 47%; males 53%). Among the 205 mutation carriers, there were 174 subjects that had a clearly defined phenotype status. Thirty mutation carriers were classified as asymptomatic and were older than 15 years and not treated with β-adrenergic receptor antagonists (β-blockers), while 9 other subjects without symptoms were too young (age <15) to be classified.21 Among the 165 subjects with a defined and classifiable phenotype, 135 had symptoms (82%) (syncope with transient but complete loss of consciousness, aborted cardiac arrest requiring resuscitation or sudden cardiac death) with a median age at first cardiac event of 6 years (IQR 4-10). Among the 135 symptomatic subjects, 56 suffered cardiac arrest and/or sudden cardiac death, and the remaining 79 symptomatic mutation carriers had only syncope. These findings are consistent with the unusual severity of this particular mutation as demonstrated by our prior analysis of 21 unrelated families from 8 different countries all carrying the KCNQ1-A341V mutation.31 One hundred-nine mutation carriers and 101 non-carriers with a resting ECG recorded in the absence of β-blocker therapy were analyzed for differences in QTc interval. Baseline QTc was longer in mutation carriers than in non-carriers (487±44 vs 402±23 ms, p<0.001) with no significant differences in mean age at the time of ECG recording or distribution of males and females between the two groups. Despite sharing the same genetic defect, mutation-carriers exhibited a wide range of QTc (397-676 ms).

Association between NOS1AP and clinical manifestations

NOS1AP variants were genotyped in 255 individuals (143 mutation carriers including 135 with a classifiable phenotype and 8 subjects younger than 15 years, and 112 non-carriers) grouped into 49 three-generation pedigrees derived from the founder population. We analyzed the association between symptoms and NOS1AP genotype using the pedigree-disequilibrium test (PDT) in 30 informative pedigrees including 29 informative triads and 102 informative discordant sibpairs that were selected by the PDT software. Two NOS1AP variants exhibited differential transmission when evaluated for association with the occurrence of cardiac symptoms (rs4657139, PDT p=0.019; rs16847548, PDT p=0.003; Table 1). After correction for multiple hypothesis testing (see Methods), only the minor allele of rs16847548 (C allele) remained significantly associated with an increased risk of cardiac events. However, these two variants (rs4657139, rs16847548) were only 6 kb apart and are in LD (D′ = 1, r2 = 0.36) among Caucasian subjects of western European ancestry genotyped by the HapMap project. Three other NOS1AP variants (rs12567206, rs10494366, rs6683968) were not significantly associated with symptoms in the South African LQTS population. The non-associated variants were either distant from the other two NOS1AP variants (rs10494366, rs6683968) or exhibited very low minor allele frequency (rs12567206; Fig. 1). The two markers with high r2 had similar MAF (31% and 32%; Fig. 1). The non-associated variants were either distant from the other two markers in NOS1AP (rs10494366, rs6683968) or exhibited very low minor allele frequency (rs12567206; Fig. 1). The two markers with high r2 had MAF values of 31% and 32% (Fig. 1).

Table 1
Pedigree dysequilibrium test for the association between NOS1AP variants and symptoms in a South African LQTS population.

We further tested whether the NOS1AP risk alleles at rs4657139 and rs16847548 were associated with the occurrence of severe cardiac events (cardiac arrest, sudden death) among symptomatic KCNQ1-A341V mutations carriers. In this analysis, rs4657139 and rs16847548 were both significantly associated with the risk of life-threatening events (rs4657139, PDT p=0.028; rs16847548, PDT p=0.014) suggesting that NOS1AP variants modify risk for life-threatening cardiac events in this Afrikaner LQTS population. We cannot compute a relative risk for life-threatening events caused by the presence of the risk allele because mutation carriers are related, which produces a risk that is biased upwards. However, an odds ratio (OR) can be considered the upper bound of the risk calculated using unrelated symptomatic subjects. With that caveat, mutation carriers with at least one copy of the minor allele at rs16847548 or rs4657139 have a 1.4 (95% C.I. 0.76-2.6) or 1.8 times (95% C.I. 1.1-3.3) greater chance of having life-threatening events than the mutation carriers without the minor allele, respectively.

Association between NOS1AP and QT interval

We also tested for association between the two NOS1AP variants that were associated with symptoms and the QTc. We examined allele sharing between two groups of KCNQ1-A341V mutation carriers defined by the upper and lower 40% of QTc values. We did not consider the central quintile in this analysis to avoid the inclusion of a confounding “grey area”. Therefore, this analysis only included mutation carriers with QTc ≤ 472 ms or QTc > 492 ms as measured by a resting electrocardiogram in the absence of β-blockers (n=118) to avoid the confounding effects of treatment. Among 21 informative pedigrees included in this analysis, there were 14 informative triads and 49 informative discordant sibpairs.

Minor alleles of the two NOS1AP variants associated with symptoms were significantly associated with a QTc greater than 492 ms in the population, (rs4657139, PDT p=0.03; rs16847548, PDT p=0.03; Table 2) which is consistent with the effect of these variants on QTc observed in healthy populations.9-18 Importantly, QTc prolongation associated with NOS1AP was observed in subjects despite an already markedly prolonged QTc interval.

Table 2
Pedigree dysequilibrium test for the association between NOS1AP variants and QTc interval (QTc ≥ 493 ms vs QTc ≤ 472 ms) in KCNQ1-A341V mutation-carriers.

Discussion

The main finding of our study is that common NOS1AP variants are modifiers of the clinical severity of congenital LQTS and are associated with a greater chance of having a more prolonged QT interval in mutation carriers. This is the first evidence, demonstrated in subjects sharing the same mutation, that NOS1AP variants are associated with a greater risk for cardiac arrest and sudden death in LQTS. These findings may contribute to the refinement of individual risk stratification in LQTS and help prompt consideration of new mechanistic hypotheses of arrhythmia susceptibility in this disease.

NOS1AP and the clinical manifestations of LQTS

Inherited arrhythmia susceptibility, such as in LQTS, is a known cause of sudden cardiac death especially in young adults and children. Accurate risk stratification is critically important for effective utilization of preventive strategies, but even among subjects found to carry the same LQTS mutation the probability of life-threatening cardiac events can vary considerably. This clinical heterogeneity can be explained in rare cases by compound heterozygosity,4,6 but common genetic factors other than the primary disease-causing mutation are also likely modifiers of arrhythmic risk. Defining genetic modifiers of LQTS could have a significant impact on the accuracy of individual risk stratification.

We had the opportunity to test NOS1AP as a candidate LQTS modifier gene in a large group of subjects carrying the same mutation as the underlying cause for arrhythmia susceptibility. This unique study design eliminates the confounding effects of genetic and allelic heterogeneity that is present when a study involves multiple different disease-causing mutations that are known to carry widely different arrhythmic risk.22,24 We specifically studied an LQT1 founder population harboring a mutation in KCNQ1 (A341V) that exhibits a wide range of QTc values and clinical manifestations.21,31 The novel finding is that the minor allele at common NOS1AP variant rs16847548 is associated with the risk of cardiac events, and – importantly - with the occurrence of life-threatening events. These findings are in agreement with the association of rs16847548 with the risk of sudden cardiac death demonstrated in a general population of white Americans.19

NOS1AP and the QT interval in LQTS

We also observed an association between the minor allele of two NOS1AP variants (rs4657139 and rs16847548) with the probability of having QTc duration in the top 40% of all QTc values among mutation carriers. Although this observation may not seem surprising at first glance given the prior associations with QT duration in general populations, we regarded this finding as somewhat unexpected. Whereas a modest effect on QT duration was detectable in very large populations having mean QT values within a normal range, we were not certain that an association of NOS1AP with QT could be detected in an LQTS population with a mean QTc value close to 500 ms because of a predicted “ceiling effect” in which the contribution of the underlying mutation to QT interval duration might dwarf any minor effect of NOS1AP variation. This is why we were impressed by the fact that, even with a small sample size and analyzing QTc as a categorical variable, the association of rs4657139 and rs16847548 with QTc could be demonstrated in our LQTS population.

Potential biological influence of NOS1AP genetic variants

There is scant information regarding the biological influence of NOS1AP genetic variation on function or expression of the gene and how this relates to effects on the QT interval or risk for cardiac events. Because NOS1AP variants associated with the QT interval are located in non-coding regions of the gene, the presumption is that transcriptional influences exerted by cis-acting elements may differ among alleles. Work from laboratories investigating genetic associations between NOS1AP and schizophrenia have elucidated potential transcriptional effects of certain common variants by using in vitro reporter-gene experiments. Specifically, the A allele of one variant (rs12742393) located in the second intron enhances binding of a presumed nuclear transcription factor and drives greater transcriptional activity of the NOS1AP promoter in human neural cell lines.32 Similar studies using cardiac tissue have not been published.

Although the potential transcriptional effects of NOS1AP variants on gene expression in heart are not known, Chang et al. found that over-expression of the NOS1AP gene product (CAPON) in isolated guinea pig myocytes causes attenuation of L-type calcium current, a slight increase in rapid delayed rectifier current (IKr) and shortening of action potentials.33 These observations suggest plausible cellular mechanisms that might explain our findings in this study. For example, if we postulate that genetic variants in NOS1AP impair expression and lead to lower levels of CAPON, then based on the study by Chang et al., we might expect increased L-type calcium current with associated arrhythmogenic consequences. Further, as calcium current is enhanced by sympathetic activation, a greater effect would be anticipated in conditions associated with augmented catecholamine release such as physical or emotional stress, the predominant clinical circumstances associated with lethal arrhythmic episodes in LQT1.23

Study Limitations

By studying this highly unique founder population, we take advantage of genetic homogeneity, essential for assessing the contribution of potential modifiers. However, the limitation of this approach is that the feasibility of performing a comparable replication study is extremely low. Whether our findings made in this founder population will apply to LQTS mutation carriers in other populations remains to be determined. Because of the restricted size of our study population, the statistical power of the data was insufficient to test all known NOS1AP variants previously associated with variation of QT duration or an unlimited number of other candidate variants. Further, a much larger population would have been required to examine effects of NOS1AP variants on the QT interval analyzed as a continuous variable. Ascertainment bias could have influenced our results, because subjects carrying both KCNQ1-A341V and the NOS1AP risk allele have a greater probability of sudden death. But, this potential bias would have actually diminished our chances of observing a significant association. This suggests conceptually that our findings are robust to any selection bias imposed by the greater risk of death in such carriers.

Conclusion

We have demonstrated a significant association between common variants in NOS1AP and the clinical severity of LQTS with special reference to life-threatening arrhythmias. The association of NOS1AP genetic variants with risk for life-threatening arrhythmias points to NOS1AP as a genetic modifier of LQTS and this knowledge should become clinically useful for risk-stratification after validation in other LQTS populations.

Acknowledgments

The authors thank Chiara Ferrandi for technical and computational assistance and Joseph Knadler for help with pedigrees.

FUNDING SOURCES: This work was support by NIH grants HL068880 (A.L.G and P.J.S.), NS27941 and MH48858 (D.A.G.), and by financial support of Telethon – Italy (Grant no. GGP07016).

Footnotes

DISCLOSURES: The authors have no conflicts of interest to disclose.

Clinical Summary: Congenital long-QT syndrome (LQTS) is a type of heritable primary cardiac arrhythmia susceptibility disease and a known cause of sudden death especially in young adults and children. Among subjects found to carry the same mutation, the probability of life-threatening cardiac events can vary considerably leading to the hypothesis that genetic factors other than the primary disease-causing mutation may modify arrhythmic risk in LQTS. Common genetic variants in NOS1AP are associated with the QT interval duration in the general population, and in this study, we tested whether NOS1AP variants modify the risk of clinical manifestations and the degree of QT interval prolongation in members of a large South African LQTS population all carrying the same mutation (KCNQ1-A341V). We found that the minor alleles of two NOS1AP variants were associated with increased risk of life-threatening events and with the probability of having a rate-corrected QT interval in the upper 40th percentile (> 492 ms) of values in the study population. These observations indicate that NOS1AP is a genetic modifier of LQTS and this knowledge should become clinically useful for risk-stratification after validation in other LQTS populations.

References

1. Schwartz PJ, Crotti L. Long QT and short QT syndrome. In: Zipes DP, Jalife J, editors. Cardiac Electrophysiology: From Cell to Bedside. 5th. Philadelphia: Elsevier/Saunders; 2009. pp. 731–744.
2. Wang Q, Curran ME, Splawski I, Burn TC, Millholland JM, VanRaay TJ, Shen J, Timothy KW, Vincent GM, de Jager T, Schwartz PJ, Towbin JA, Moss AJ, Atkinson DL, Landes GM, Connors TD, Keating MT. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nature Genet. 1996;12:17–23. [PubMed]
3. Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-QT syndrome: clinical impact. Circulation. 1999;99:529–533. [PubMed]
4. Schwartz PJ, Priori SG, Napolitano C. How really rare are rare diseases?: the intriguing case of independent compound mutations in the long QT syndrome. J Cardiovasc Electrophysiol. 2003;14:1120–1121. [PubMed]
5. Crotti L, Lundquist AL, Insolia R, Pedrazzini M, Ferrandi C, De Ferrari GM, Vicentini A, Yang P, Roden DM, George AL, Jr, Schwartz PJ. KCNH2-K897T is a genetic modifier of latent congenital long-QT syndrome. Circulation. 2005;112:1251–1258. [PubMed]
6. Westenskow P, Splawski I, Timothy KW, Keating MT, Sanguinetti MC. Compound mutations: a common cause of severe long-QT syndrome. Circulation. 2004;109:1834–1841. [PubMed]
7. Schwartz PJ, Wolf S. QT interval prolongation as predictor of sudden death in patients with myocardial infarction. Circulation. 1978;57:1074–1077. [PubMed]
8. Chugh SS, Reinier K, Singh T, Uy-Evanado A, Socoteanu C, Peters D, Mariani R, Gunson K, Jui J. Determinants of prolonged QT interval and their contribution to sudden death risk in coronary artery disease: the Oregon Sudden Unexpected Death Study. Circulation. 2009;119:663–670. [PMC free article] [PubMed]
9. Arking DE, Pfeufer A, Post W, Kao WH, Newton-Cheh C, Ikeda M, West K, Kashuk C, Akyol M, Perz S, Jalilzadeh S, Illig T, Gieger C, Guo CY, Larson MG, Wichmann HE, Marban E, O'Donnell CJ, Hirschhorn JN, Kaab S, Spooner PM, Meitinger T, Chakravarti A. A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization. Nature Genet. 2006;38:644–651. [PubMed]
10. Aarnoudse AJ, Newton-Cheh C, De Bakker PI, Straus SM, Kors JA, Hofman A, Uitterlinden AG, Witteman JC, Stricker BH. Common NOS1AP variants are associated with a prolonged QTc interval in the Rotterdam Study. Circulation. 2007;116:10–16. [PubMed]
11. Post W, Shen H, Damcott C, Arking DE, Kao WH, Sack PA, Ryan KA, Chakravarti A, Mitchell BD, Shuldiner AR. Associations between genetic variants in the NOS1AP (CAPON) gene and cardiac repolarization in the old order Amish. Hum Hered. 2007;64:214–219. [PMC free article] [PubMed]
12. Raitakari OT, Blom-Nyholm J, Koskinen TA, Kahonen M, Viikari JS, Lehtimaki T. Common variation in NOS1AP and KCNH2 genes and QT interval duration in young adults. The Cardiovascular Risk in Young Finns Study. Ann Med. 2008;41:144–151. [PubMed]
13. Tobin MD, Kahonen M, Braund P, Nieminen T, Hajat C, Tomaszewski M, Viik J, Lehtinen R, Ng GA, Macfarlane PW, Burton PR, Lehtimaki T, Samani NJ. Gender and effects of a common genetic variant in the NOS1 regulator NOS1AP on cardiac repolarization in 3761 individuals from two independent populations. Int J Epidemiol. 2008;37:1132–1141. [PubMed]
14. Lehtinen AB, Newton-Cheh C, Ziegler JT, Langefeld CD, Freedman BI, Daniel KR, Herrington DM, Bowden DW. Association of NOS1AP genetic variants with QT interval duration in families from the Diabetes Heart Study. Diabetes. 2008;57:1108–1114. [PubMed]
15. Arking DE, Khera A, Xing C, Kao WH, Post W, Boerwinkle E, Chakravarti A. Multiple independent genetic factors at NOS1AP modulate the QT interval in a multi-ethnic population. PLoS ONE. 2009;4:e4333. [PMC free article] [PubMed]
16. Eijgelsheim M, Aarnoudse AL, Rivadeneira F, Kors JA, Witteman JC, Hofman A, van Duijn CM, Uitterlinden AG, Stricker BH. Identification of a common variant at the NOS1AP locus strongly associated to QT-interval duration. Hum Mol Genet. 2009;18:347–357. [PubMed]
17. Newton-Cheh C, Eijgelsheim M, Rice KM, De Bakker PI, Yin X, Estrada K, Bis JC, Marciante K, Rivadeneira F, Noseworthy PA, Sotoodehnia N, Smith NL, Rotter JI, Kors JA, Witteman JC, Hofman A, Heckbert SR, O'Donnell CJ, Uitterlinden AG, Psaty BM, Lumley T, Larson MG, Stricker BH. Common variants at ten loci influence QT interval duration in the QTGEN Study. Nature Genet. 2009;41:399–406. [PMC free article] [PubMed]
18. Pfeufer A, Sanna S, Arking DE, Muller M, Gateva V, Fuchsberger C, Ehret GB, Orru M, Pattaro C, Kottgen A, Perz S, Usala G, Barbalic M, Li M, Putz B, Scuteri A, Prineas RJ, Sinner MF, Gieger C, Najjar SS, Kao WH, Muhleisen TW, Dei M, Happle C, Mohlenkamp S, Crisponi L, Erbel R, Jockel KH, Naitza S, Steinbeck G, Marroni F, Hicks AA, Lakatta E, Muller-Myhsok B, Pramstaller PP, Wichmann HE, Schlessinger D, Boerwinkle E, Meitinger T, Uda M, Coresh J, Kaab S, Abecasis GR, Chakravarti A. Common variants at ten loci modulate the QT interval duration in the QTSCD Study. Nature Genet. 2009;41:407–414. [PMC free article] [PubMed]
19. Kao WH, Arking DE, Post W, Rea TD, Sotoodehnia N, Prineas RJ, Bishe B, Doan BQ, Boerwinkle E, Psaty BM, Tomaselli GF, Coresh J, Siscovick DS, Marban E, Spooner PM, Burke GL, Chakravarti A. Genetic variations in nitric oxide synthase 1 adaptor protein are associated with sudden cardiac death in US white community-based populations. Circulation. 2009;119:940–951. [PMC free article] [PubMed]
20. Becker ML, Visser LE, Newton-Cheh C, Hofman A, Uitterlinden AG, Witteman JC, Stricker BH. A common NOS1AP genetic polymorphism is associated with increased cardiovascular mortality in users of dihydropyridine calcium channel blockers. Br J Clin Pharmacol. 2009;67:61–67. [PMC free article] [PubMed]
21. Brink PA, Crotti L, Corfield V, Goosen A, Durrheim G, Hedley P, Heradien M, Geldenhuys G, Vanoli E, Bacchini S, Spazzolini C, Lundquist AL, Roden DM, George AL, Jr, Schwartz PJ. Phenotypic variability and unusual clinical severity of congenital long-QT syndrome in a founder population. Circulation. 2005;112:2602–2610. [PubMed]
22. Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M, Vicentini A, Spazzolini C, Nastoli J, Bottelli G, Folli R, Cappelletti D. Risk stratification in the long-QT syndrome. N Engl J Med. 2003;348:1866–1874. [PubMed]
23. Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, Denjoy I, Guicheney P, Breithardt G, Keating MT, Towbin JA, Beggs AH, Brink P, Wilde AA, Toivonen L, Zareba W, Robinson JL, Timothy KW, Corfield V, Wattanasirichaigoon D, Corbett C, Haverkamp W, Schulze-Bahr E, Lehmann MH, Schwartz K, Coumel P, Bloise R. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation. 2001;103:89–95. [PubMed]
24. Moss AJ, Shimizu W, Wilde AA, Towbin JA, Zareba W, Robinson JL, Qi M, Vincent GM, Ackerman MJ, Kaufman ES, Hofman N, Seth R, Kamakura S, Miyamoto Y, Goldenberg I, Andrews ML, McNitt S. Clinical Aspects of Type-1 Long-QT Syndrome by Location, Coding Type, and Biophysical Function of Mutations Involving the KCNQ1 Gene. Circulation. 2007;115:2481–2489. [PMC free article] [PubMed]
25. Newton-Cheh C, Guo CY, Wang TJ, O'Donnell CJ, Levy D, Larson MG. Genome-wide association study of electrocardiographic and heart rate variability traits: the Framingham Heart Study. BMC Med Genet. 2007;8(Suppl I):S7. [PMC free article] [PubMed]
26. Martin ER, Monks SA, Warren LL, Kaplan NL. A test for linkage and association in general pedigrees: the pedigree disequilibrium test. Am J Hum Genet. 2000;67:146–154. [PubMed]
27. Hardy SW, Weir BS, Kaplan NL, Martin ER. Analysis of single nucleotide polymorphisms in candidate genes using the pedigree disequilibrium test. Genet Epidemiol. 2001;21(Suppl 1):S441–S446. [PubMed]
28. Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet. 2004;74:765–769. [PubMed]
29. Li J, Ji L. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity. 2005;95:221–227. [PubMed]
30. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D. The structure of haplotype blocks in the human genome. Science. 2002;296:2225–2229. [PubMed]
31. Crotti L, Spazzolini C, Schwartz PJ, Shimizu W, Denjoy I, Schulze-Bahr E, Zaklyazminskaya EV, Swan H, Ackerman MJ, Moss AJ, Wilde AA, Horie M, Brink PA, Insolia R, De Ferrari GM, Crimi G. The common long-QT syndrome mutation KCNQ1/A341V causes unusually severe clinical manifestations in patients with different ethnic backgrounds: toward a mutation-specific risk stratification. Circulation. 2007;116:2366–2375. [PubMed]
32. Wratten NS, Memoli H, Huang Y, Dulencin AM, Matteson PG, Cornacchia MA, Azaro MA, Messenger J, Hayter JE, Bassett AS, Buyske S, Millonig JH, Vieland VJ, Brzustowicz LM. Identification of a schizophrenia-associated functional noncoding variant in NOS1AP. Am J Psychiatry. 2009;166:434–441. [PMC free article] [PubMed]
33. Chang KC, Barth AS, Sasano T, Kizana E, Kashiwakura Y, Zhang Y, Foster DB, Marban E. CAPON modulates cardiac repolarization via neuronal nitric oxide synthase signaling in the heart. Proc Natl Acad Sci U S A. 2008;105:4477–4482. [PubMed]